You are here:
NICE
NICE Guidance
Published Guidance
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Technology appraisal guidance
Reference number:
TA619
Published:
15 January 2020
This guidance has been updated and replaced by
NICE technology appraisal guidance 836
.